The loss came in at more than double consensus, missing expectations on non-cash charges including the Ascendant top-up share obligation revaluation and performance equity grants from the Q2 strategic overhaul. With collaboration revenue nearly gone as Boehringer Ingelheim activity winds down, $57.9 million in cash has to carry CUE-221 into food allergy trials after FDA IND clearance.
Latest Activity
CUE Coverage
The VIX Sharply Reverses and Points Back Towards 30 After Failed Peace Negotiations
The CBOE Volatility Index (VIX) is reversing sharply this Monday morning, spiking more than 7% after weekend negotiations between the U.S. and Iran collapsed following 21 hours of talks, sending the fear…